Myasthenia Gravis

Latest News

doctor and patient | Image Credit: © Halfpoint - stock.adobe.com
Understanding Patient Perspectives Around Myasthenia Gravis Treatment May Help Optimize Care

November 20th 2024

Patients with myasthenia gravis (MG) largely expressed negative emotions around MG treatment and symptom burden in patient focus groups and on MG social media discussion boards.

Global health | Image Credit: © zephyr_p - stock.adobe.com
Worldwide Incidence, Prevalence of MG Has More Than Doubled Since 1950s

November 14th 2024

AI graphic | Image Credit: © NicoElNino-stock.adobe.com
Enhancing Myasthenia Gravis Care With AI-Powered Telemedicine

November 8th 2024

Myasthenia gravis | Image Credit: © lexiconimages-stock.adobe.com
COVID-19 Exacerbations in Myasthenia Gravis Linked to Severity

November 5th 2024

MG notes concept | image credit: Andrii - stock.adobe.com
Rozanolixizumab Effective in Patients With MuSK MG, Analysis Shows

October 23rd 2024

More News

Myasthenia Gravis | Image Credit: luchschenF-stock.adobe.com
May 13th 2024

Case Report: Upper Extremity DVT in Patient With Seronegative MG

AJMC Contributor
In addition to her advanced age and obesity status, the patient had a history of pulmonary embolism managed with an inferior vena cava filter, increasing her risk of thrombosis.
Concept of Myasthenia Gravis | Image Credit: © syahrir - stock.adobe.com
May 1st 2024

Extension Trial Shows Zilucoplan Safe and Effective for MG at 60 Weeks

Jared Kaltwasser
COVID-19 and worsening myasthenia gravis (MG) were the most common treatment-emergent adverse events, the study found.
Diagnosis myasthenia gravis | Image Credit: Николай Зотов - stock.adobe.com
April 27th 2024

UK Study: Most Patients With MG Require Hospitalization, Driving Health Care Resource Use

AJMC Contributor
Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.
Case study graphic | Image Credit: STOATPHOTO - stock.adobe.com
April 19th 2024

Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome

Luke Halpern
A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Myasthenia gravis photo | Image Credit: syahrir - stock.adobe.com
April 15th 2024

Long-Term Data Affirm Efficacy of Eculizumab in Refractory Generalized MG

Jared Kaltwasser
A new survey has found that most patients who have generalized myasthenia gravis who switched from eculizumab to ravulizumab preferred the latter.
term myasthenia gravis | Image Credit: lexiconimages - stock.adobe.com
April 11th 2024

Bioinformatics, Machine Learning Reveal New Insights Into MG-Associated DCM

AJMC Contributor
Researchers explain that these insights have important implications, if validated in further research, as challenges with early detection of dilated cardiomyopathy complicate myasthenia gravis (MG)-prognosis.
Myasthenia gravis | Image Credit: Andrii - stock.adobe.com
April 6th 2024

Online Discussions Illuminate Daily Challenges, Treatment Hurdles in MG

AJMC Contributor
Analyzing trends from online conversations among patients with myasthenia gravis (MG), researchers found that issues with current treatments were mentioned in nearly 24% of conversations.
myasthenia gravis | Image Credit: luchschenF - stock.adobe.com
March 28th 2024

Patients With Autoimmune Thyroid Disease at Higher Risk of Myasthenia Gravis

AJMC Contributor
These insights, explain the researchers of the study, complement observational studies, which have previously indicated a causal relationship between the 2 diseases.
Myasthenia Gravis with phrase on the page | Image Credit: Yurii Kibalnik - stock.adobe.com
March 23rd 2024

Researchers Highlight Current Gaps in Research on Exercise Use in MG

AJMC Contributor
The researchers note that their findings can help inform adjustments for future research among individuals living with myasthenia gravis (MG).
Myasthenia gravis stock image | Image Credit: lhphotos - stock.adobe.com
March 21st 2024

Pilot Study Links Possible Lab Markers With Risk of Myasthenic Crisis

AJMC Contributor
These findings, together with real-world data, could help inform risk classification of myasthenic crisis beyond known risk factors, such as infection.
Older man and doctor on telehealth visit | Image Credit: fizkes - stock.adobe.com
March 13th 2024

Rising Myasthenia Gravis Rates in Older US Men Spark Research, Public Health Concerns

Gwen Mergian
Incidence and prevalence of myasthenia gravis in the US has increased surprisingly since last examined more than 20 years ago.
Concept of Myasthenia Gravis writing on sticky notes isolated on Wooden Table | Image credit: syahrir - stock.adobe.com
March 8th 2024

Review: Vigilance Warranted to Prevent, Treat Transient Neonatal Myasthenia Gravis

Jared Kaltwasser
Preventive measures can reduce the risk to newborns, but careful monitoring is necessary, the authors said.
Conceptual photo about Myasthenia Gravis | Image credit: Yurii Kibalnik-stock.adobe.com.jpeg
March 5th 2024

Batoclimab Outperforms Placebo in Phase 3 Generalized MG Trial

Jared Kaltwasser
The fully humanized monoclonal antibody led to results among patients with generalized myasthenia gravis (MG) similar to that of efgartigimod, the authors said.
Gut microbiome - sdecoret - stock.adobe.com
February 29th 2024

Analysis Identifies Gut Microbiota Affecting Risk of MG

AJMC Contributor
The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.
Graphical representation of autoantibody diseases | Image credit: lexiconimages - stock.adobe.com
February 29th 2024

Intravenous Nipocalimab Infusions Safe, Effective Against Autoantibody-Mediated Diseases

Luke Halpern
After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter treatment periods and with larger doses.
Myasthenia gravis | Image credit: Andrii - stock.adobe.com
February 22nd 2024

Phase 2 Results Show Safety, Dose-Dependent Improvements in Function With Nipocalimab in gMG

AJMC Contributor
Based on data from the study, a phase 3 confirmatory trial is underway for the humanized monoclonal antibody.
Myasthenia gravis report | Image credit: mdaros - stock.adobe.com
February 15th 2024

Vyvgart Phase 3 Extension Study Data Affirm Long-Term Safety, Efficacy in gMG

AJMC Staff
Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.
MYASTHENIA GRAVIS inscription on the black board Image credit: Yurii Kibalnik - stock.adobe.com
February 9th 2024

Phase 3 Trial Will Assess Whether Humanized mAb Addresses Patient Needs in MG

AJMC Staff
Dubbed the FLEX trial, the study will explore whether batoclimab will address important patient needs throughout different phases of the myasthenia gravis (MG).
Myasthenia Gravis illustration isolated on red background | Image credit: lhphotos - stock.adobe.com
February 6th 2024

Possible Increase in Prevalence of Alzheimer Disease Found in Patients With Myasthenia Gravis

Luke Halpern
Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.
Myasthenia gravis | Image credit: lexiconimages - stock.adobe.com
January 31st 2024

IV Methylprednisolone, Tacrolimus Effective in Prednisone-Resistant Ocular MG

AJMC Staff
Researchers have retrospectively analyzed data from nearly 60 patients with ocular myasthenia gravis (MG) not adequately responding to oral prednisone, finding that both intravenous (IV) methylprednisolone and tacrolimus monotherapy helped reduce symptoms.
Old man with eye fatigue | Image Credit: sebra - stock.adobe.com
January 30th 2024

Overlapping Symptoms Challenge Diagnosis in Rare Co-Occurrence of PD, MG

Gwen Mergian
Since 1987, only 57 cases of comorbid Parkinson disease (PD) and myasthenia gravis (MG) have been reported.
Diagnosis: Myasthenia Gravis | Image Credit: © Николай Зотов - stock.adobe.com
January 27th 2024

New MG Research Focuses on More Tailored Treatment, Bibliometric Analysis Finds

AJMC Staff
The data search of Web of Science Core Collection, spanning 2003 to 2022, identified various prospective directions in myasthenia gravis (MG) research, including in personalized treatment, subtype-based treatment, and novel immunotherapeutic strategies.
Myasthenia gravis | Image credit: Andrii - stock.adobe.com
January 25th 2024

Claims Data Suggest High Clinical, Economic Burden of MG Exacerbations Despite Treatment Options

AJMC Staff
The data suggest this burden among patients who have myasthenia gravis (MG) is prevalent across insurance types.
Faceless male patient speaking with doctor holding a clipboard | DragonImages - adobe.stock.com
January 19th 2024

New Therapies More Precisely Treat Myasthenia Gravis

Laura Joszt, MA
Once treated with a one-size-fits-all approach, changes in the landscape for myasthenia gravis are allowing for more precise treatment of the disease.
Notes on myasthenia gravis | Image Credit: syahrir - stock.adobe.com
December 29th 2023

Low-Dose Rituximab Effective Against MuSK-Positive MG in New Analysis

Maggie L. Shaw
Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.
Graphic representing the top 5 myasthenia gravis articles of 2023
December 18th 2023

Top 5 Most-Read Myasthenia Gravis Articles of 2023

Maggie L. Shaw
In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.
Myasthenia gravis blood test | Image credit: luchschenF - stocka.adobe.com
December 15th 2023

New Data on Batoclimab for MG Indicate Effective Treatment Potential

Maggie L. Shaw
Two doses of batoclimab were evaluated for their effectiveness in patients with generalized myasthenia gravis (MG) who were seropositive.
Myasthenia gravis diagnosis | Image Credit: Andrii - stock.adobe.com
December 6th 2023

Myasthenia Gravis Trial Set for CAR T CABA-201

Noah Stansfield
The chimeric antigen receptor T-cell therapy (CAR T) from Cabaletta Bio has already been cleared for trials in systemic lupus erythematosus, myositis, and systemic sclerosis.
The words "Diagnosis: Myasthenia Gravis" on a notebook with a stethoscope and pills | Image Credit: Николай Зотов stock.adobe.com
December 3rd 2023

New Data Update Myasthenia Gravis Outcomes for Patients in Australia

Maggie L. Shaw
Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.
Patient-Specific Therapy Model | image credit: vrx123 - stock.adobe.com
December 1st 2023

Patient-Specific Targeted Therapies Could Mitigate Immune-Related Adverse Events

Kyle Munz
A case report highlights the benefits of applying patient-tailored therapies to mitigate the effects of neuromuscular immune-related adverse events and improve patient outcomes.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo